Anti-P30-52 monoclonal antibody cross-reacted to Env V3 and inhibited the viral multiplication of HIV-1-infected MT-4 cells

Hybridoma

Volumn 18, Issue 2, 1999, Pages 139-147

  Ota, Akemi ^a   Bautista, Analisa N ^a   Yadav, Munar Lal ^a   Ueda, Sigeharu ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; DNA FRAGMENT; ENVELOPE PROTEIN; GLYCOPROTEIN; MONOCLONAL ANTIBODY; VIRUS VACCINE;

ANIMAL CELL; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIBODY TITER; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL CULTURE; CELL DEATH; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; KINETICS; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; VACCINATION; VIROGENESIS; VIRUS CULTURE; VIRUS INHIBITION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE; RNA VIRUSES;

EID: 0033023137     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1999.18.139     Document Type: Article

References (47)

1. Wills JW and Craven RC: Form, function, and use of retroviral Gag proteins AIDS 1991;5:639-654.
2. Wagner R, Fliessbach B, Wanner G, Motz M, Niedrig M, Deby G, von Brunn A, and Wolf H: Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: A possible component of a HIV vaccine. Arch Virol 1992;127:117-137.
3. Yu X, Yuan X, Matsuda Z, Lee T, and Essex M: The matrix protein of human Immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol 1992;66:4966-4971.
4. Dorfman T, Mammano F, Haseltine WA, and Gottlinger HG: Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein. J Virol 1994;68:1689-1696.
5. Truong C, Brand D, Mallet F, Roingeard P, Brunet S, and Barin F: Assembly and immunogenicity of chimeric Gag-Env proteins derived from the human immunodeficiency virus type 1. AIDS Res Hum Retro 1995;12:291-301.
6. Kattenbeck B, Rohrhofer A, Neidrig M, Wolf H, and Modrow S: Defined amino acid in the gag proteins of human immunodeficiency virus type 1 are functionally active during virus assembly. Intervirology 1996;39:32-39.
7. Reicin AS, Ohagen A, Yin L, Hoglund S, and Goff SP: The role of gag in human immunodeficiency virus type 1 virion morphogenesis and early steps of the viral life cycle. J Virol 1996;70:8645-8652.
8. Ono A, Huang M, and Freed EO: Characterization of human immunodeficiency virus type 1 matrix revertants: Effects on virus assembly. Gag processing, and Env incorporation into virions. J Virol 1997;71:4409-4418.
9. Kiernan RE, Ono A, Englund G, and Freed EO: Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle. J Virol 1998;72:4116-4126.
10. Gallina A, Mantoan G, Rindi G, and Milanesi G: Influence of MA internal sequences, but not of the myristylated N-terminus sequence, on the budding site of HIV-1 gag protein. Biochem Biophys Res Comm 1994;204:1031-1038.
11. Zhou W, and Resh MD: Differential membrane binding of the human immunodeficiency virus type 1 matrix protein. J Virol 1996;70:8540-8548.
12. Spearman P, Horton R, Ratner L, and Kuli-Zade I: Membrane binding of human immunodeficiency virus type 1 matrix protein in vivo supports a conformational myristyl switch mechanism. J Virol 1997;71:6582-6592.
13. Bukrinsky MI, Haggerty S, Dempsey MP, Sharova N, Adzhubei A, Spitz L, Lewis P, Goldfarb D, Emerman M, and Stevenson M: A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 1993;365:666-669.
14. Gulizia J, Dempsey MP, Sharova N, Bukrinsky MI, Spitz L, Goldfarb D, and Stevenson M: Reduced nuclear import of human immunodeficiency virus type 1 preintegration complexes in the presence of a prototypic nuclear targeting signal. J Virol 1994;68:2021-2025.
15. Gallay P, Stitt V, Mundy C, Oettinger M, and Trono D: Role of the Karyopherin pathway in human immunodeficiency virus type 1 nuclear import. J Virol 1996;70:1027-1032.
16. Schwedler U, Kornbluth RS, and Trono D: The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc Natl Acad Sci USA 1994;91:6992-6996.
17. Fouchier RAM, Meyer BE, Simon JHM, Fischer U, and Malim MH: HIV-1 infection of non-dividing cells: Evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. EMBO 1997;16:4531-4539.
18. Burnette B, Yu G, and Felsted RL: Phosphorylation of HIV-1 gag proteins by protein kinase C. J Biol Chem 1993;268:8698-8703.
19. Gallay P, Swingler S, Aiken C, and Trono D: HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell 1995;80:379-388.
20. Bukrinskaya AG, Ghorpade A, Heinzinger NK, Smithgal TE, Lewis RE, and Stevenson M: Phosphorylation-dependent human immunodeficiency virus type 1 infection and nuclear targeting of viral DNA. Proc Natl Acad Sci USA 1996;93:367-371.
21. Swingler S, Gallay P, Camaur D, Song J, Abo A, and Trono D: The nef protein of human immunodeficiency virus type 1 enhances serine phosphorylation of the viral matrix. J Virol 1997;71: 4372-4377.
22. Lange JMA, de Wolf F, Krone WJA, Danner SA, Coutinho RA, and Goudsmint J: Decline of antibody reactivity to outer viral core protein p17 is an earlier serological marker of disease progression in human immunodeficiency virus infection than anti-p24 decline. AIDS 1987;1:155-159.
23. Choudhury AM, Yamada O, Wakamiya N, and Kurimura T: A prospective study on correlation between the decrease in anti-p17 antibody level and progression to AIDS in asymptomatic carriers of HIV. Microbiol Immunol 1992;36:833-840.
24. Chargelegue D, Stanley CM, O'toole CM, Colvin BT, and Steward MW: The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression. Clin Exp Immunol 1995;99:175-181.
25. Massiah MA, Starich MR, Paschall C, Summers MF, Christensen AM, and Sundquist WI: Three-dimensional structure of the Human Immunodeficiency Virus type 1 matrix protein. J Mol Biol 1994;244:198-223.
26. Rao Z, Belyaev AS, Fry E, Roy P, Jones IM, and Stuart DI: Crystal structure of SIV matrix antigen and implications for virus assembly. Nature 1995;378:743-747.
27. Massiah MA, Worthylake D, Christensen AM, Sundquist WI, Hill CP, and Summers MF: Comparison of the NMR and x-ray structures of the HIV-1 protein: Evidence for conformational changes during viral assembly. Protein Sci 1996;5:2391-2398.
28. Hill CP, Worthylake D, Bancroft DP, Christensen AM, and Sundquest WI: Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: Implications for membrane association and assembly. Pro Natl Acad Sci USA 1996;93:3099-3104.
29. Cannon PM, Matthews S, Clark N, Byles ED, Jourin O, Hockley DJ, Kingsman SM, and Kingsman AJ: Structure-function studies of the human immunodeficiency virus type 1 matrix protein p17. J Virol 1997;71:3474-3483.
30. Liu X, Ota A, Watanabe M, Ueda S, Saitoh A, Shinagawa H, Nakata A, Kurimura T, Wang X, Zhao Y, Kondo K, Seki J, Miyake S, Sakato N, and Fujio H: Three antigenic regions in p17 of human immunodeficiency virus type 1 (HIV-1) revealed by mouse monoclonal antibodies and human antibodies in HIV-1 carrier sera. Microbial Immunol 1995;39:775.
31. Ota A, Liu X, Fujio H, Sakato N, and Ueda S: Random expression of human immunodeficiency virus-1 (HIV-1) p17 (epitopes) on the surface of the HIV-1 infected cell. Hybridoma 1998;17:73-75.
32. Feng S, Chen JK, Yu H, Simon JA, and Schreiber SL: Two binding orientations for peptides to the Src SH3 domain: Development of a general model for SH3-ligand interactions. Science 1994;266:1241-1247.
33. Sarin PS, Sun DK, Thornton, AH, Naylor PH, and Goldstein AL: Neutralization of HTLV-III/LAV replication by antiserum to thymosin alpha 1. Science 1986;232:1135-1137.
34. Burgisser P and Frei PC: Characterization of antibodies reacting with HIV gag proteins occasionally found in the serum of non-infected subjects. Clin Exp Immunol 1991;85:219-223.
35. Matthews S, Barlow P, Boyd J, Barton G, Russell, Mills H, Cunningham M, Meyers N, Burns N, Clark N, Kingsman S, Kingsman A, and Campbell I: Structural similarity between the p17 matrix protein of HIV-1 and interferon-γ. Nature 1994;370:666-668.
36. Kato T, Kurita K, Kawanami T, and Sasaki H: Detection of a 23 kDa human brain protein that shares epitope(s) with the 17 kDa core protein of human immunodeficiency virus (HIV). Neurosci Lett 1994;181:134-136.
37. Lyden TW, Johnson PM, Mwenda JM, and Rote NS: Expression of endogenous HIV-1 crossreactive antigens within normal human extravillous trophoblast cells. J Reprod Immunol 1995;28:233-245.
38. Buratti E, Tisminetzky SG, D'agaro P, and Baralle FE: A neutralizing monoclonal antibody previously mapped exclusively on human immunodeficiency virus type 1 gp41 recognizes an epitope in p17 sharing the core sequence IEEE. J Virol 1997;71:2457-2462.
39. Kato T, Suzuki J, Daimon M, Sasaki H, and Ishikawa K: Antibodies to the HIV-1 p17 protein cross-react with human superoxide dismutase-2. Biochem Biophys Res Commun 1997;230:184-187.
40. La Rosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, Langlois AJ, Dressman GR, Boswell RN, Shadduck P, et al.: Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990;249:932-935.
41. Seki J, Wang X, Ota A, Suzuki Y, Sakato N, and Fujio H: Inducibility of protein-reactive antibodies by peptide immunization comparison of three epitope peptides of hen egg-white lysozyme. J Biochem 1992;111:259-264.
42. Ota A and Ueda S: Evaluation of the affinity measurement of anti-HIV-1 p17 monoclonal antibody by BIAcore. Hybridoma 1998;17:471-477.
43. Yamada O, Matsumoto T, Sasaoka R, and Kurimura T: Variations in growth capacity of HIV in peripheral blood mononuclear cell preparations from different individuals. AIDS 1990;4:35-40.
44. Burleson FG, Chambers TM, and Wiedbrauk DL: Virology: A laboratory manual. New York, Academic Press, Inc., 1992, pp. 54-57.
45. Burton K: A study of the conditions and mechanisms of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. J Biochem 1956;62:315-323.
46. Ghiara JB, Stura EA, Stanfield RL, Profy AT, and Wilson IA: Crystal structure of the principal neutralization site of HIV-1. Science 1994;264:82-85.
47. Garry RF, Fermin CD, Hart DJ, Alexander SS, Donehower LA, and Luo-Zhang H: Detection of a human intracisternal A-type retroviral particle antigenically related to HIV. Science 1990;250: 1127-1129.